Protocol # STERIO-SCD, A Phase lib Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients with Sickle Cell Diseases03/20/2018 - 09/19/2023 (Co-Investigator)
The University of Pittsburgh Bayer HealthCare
Assessing the effectiveness of anti-sickling agents for sickle hemoglobin and red blood cells02/01/2016 - 01/31/2022 (Co-Investigator)
PI:
Elizabeth S. Klings, MDThe General Hospital Corporation d/b/a Massachusetts General Hospital
Hematopoietic Stem Cell Transplantation for Young Adults with Sickle Cell Disease08/01/2016 - 07/31/2021 (Subcontract PI)
Emory University NIH NHLBI5U01HL128566-05
Neutrophil Elastase as a Biomarker for Neutrophil-mediated Pathbiology in Sickle Cell Disease12/21/2015 - 06/20/2021 (Co-Investigator)
Children's Hospital, Oakland Bayer HealthCare
A 5-year, prospective, non-interventional, multi-center registry in Sickle Cell Disease patients02/09/2010 - 12/31/2017 (PI)
Novartis Pharmaceuticals Corporation
Blood Samples, Blood Laboratory Test Results and Questionnaire Data from Sickle Cell Disease Blood Donors Collected under an IRB Approved Protocol with Signed Informed Consent12/06/2013 - 12/31/2016 (PI)
Biogen Idec
A Phase ll, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SeIG1 with or without Hydroxyurea Therapy in Sickle Cell Disease Patients with Si08/30/2013 - 08/31/2016 (PI)
Selexys Pharmaceuticals Corporation
A Double-Blind, Randomized, Multicenter Study of Prasugrel Compared to Placebo in Adult Patients with Sickle Cell Disease01/01/2011 - 12/31/2014 (PI)
Eli Lilly and Company
A Phase III, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of L-Glutamine Therapy for Sickle Cell Anemia and Sickle B0- Thalassemia04/01/2010 - 06/30/2014 (PI)
Emmaus Medical, Inc
A DOUBLE-BLIND, RANDOMIZED, MULTICENTER STUDY OF PRASUGREL COMPARED TO PLACEBO IN ADULT PATIENTS WITH01/01/2011 - 12/31/2013 (PI)
Eli Lilly and Company
Showing 10 of 13 results.
Show All Results
A Phase 2 randomized, double-blind, placebo-controlled study of the efficacy, safety, and pharmacokinetics of GMI-1070, a pan-selectin inhibitor, in subjects hospitalized for sickle cell vaso-occ04/01/2010 - 03/31/2012 (PI)
Glycomimetrics, Inc.
A Phase II, Multicenter, Twelve-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Range-Finding Study of the Efficacy and Safety of ICA-17043 with or without Hydorxyurea Therapy in Patients with Sickle Cell Anemia01/17/2002 - 01/16/2003 (PI)
IcaGen, Inc.
Controlled Study to Determine the Effects of Procrit kEpoetin Alfa in Patients with Sickle Cell Anemia Who are Receiving Hydroxyurea01/17/2002 - 01/16/2003 (PI)
Ortho Biotech Inc
Vertex Human Tissue Request: Sickle Cell Disease (SCD)05/25/2017 - 05/31/2023 (PI)
Vertex Pharmaceuticals
GBT440-03405/11/2018 - 05/11/2021 (PI)
Global Blood Therapeutics
GBT 44008/24/2017 - 08/24/2020 (PI)
Global Blood Therapeutics
A PHASE 1B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMAOCODYNAMICS OF PF-04447943, CO-ADMINISTERED WITH AND WITHOUT HYDROXYUREA, IN SUBJECT WITHS SICKLE CELL DISEASE05/20/2015 - 12/31/2018 (PI)
Pfizer, Inc
Boston Sickle Cell Research consortium - IMPROVE STUDY CLINICAL TRIAL09/01/2009 - 03/31/2011 (PI)
New England Res Inst NIH-NHLBI
PROACTIVE12/17/2008 - 03/31/2011 (PI)
New England Res Inst NIH-NHLBI
Boston Sickle Cell Research Consortium05/01/2006 - 03/31/2011 (PI)
NIH-NHLBI5U10 HL083771-05
Comprehensive Sickle Cell Cent01/01/1992 - 03/31/2004 (PI)
NIH-NHLBI5 P60 HL15157-30
Sickle Cell Transition Program09/30/1998 - 05/30/2002 (PI)
Brigham & Women's
Nitrite Oxide By Inhalation02/02/1999 - 02/02/2000 (PI)
INO Therapeutics(IKARIA)